Faruqi & Faruqi Issues Reminder for MoonLake Investors Ahead of December 15 Class‑Action Deadline

Faruqi & Faruqi, LLP — the national securities‑litigation firm — is alerting investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) about the fast‑approaching December 15, 2025 deadline to file for lead‑plaintiff status in a pending class‑action lawsuit. According to the firm, anyone who purchased or acquired MoonLake securities between March 10, 2024 and September 29, 2025 may be eligible. The suit alleges that MoonLake and its executives misled investors by making false or misleading statements — or by failing to disclose material information — regarding the distinctions between the company’s “Nanobody” drug candidate SLK and an existing monoclonal‑antibody therapy (BIMZELX). More specifically, the complaint claims that MoonLake overstated SLK’s potential clinical benefits, tissue‑penetration advantages, and superiority over the established drug structure. The action gained urgency after on September 28, 2025 MoonLake released Phase 3 VELA trial results showing SLK failed to match BIMZELX’s efficacy. The next day, the company’s share price collapsed — dropping $55.75 per share, a nearly 90% plunge, to close at $6.24 on September 29. Investors who believe they incurred losses are encouraged to contact Faruqi & Faruqi’s partner James (Josh) Wilson directly (877‑247‑4292 or 212‑983‑9330 ext. 1310) to explore their legal options. #MoonLake #SecuritiesLawsuit #InvestorAlert #MLTX #SlimScan #GrowthStocks #CANSLIM